Bioceltix SA (BCX) Stock Statistics & Valuation Metrics

Bioceltix SA has a market cap or net worth of zł487.94M. The enterprise value is zł386.11M.

Bioceltix SA has 5,532,253 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bioceltix SA’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -23.48%.

The current PE Ratio of Bioceltix SA is ―. Bioceltix SA’s PEG ratio is 3.36.

In the last 12 months, Bioceltix SA had revenue of 0.00 and earned -15.16M in profits. Earnings per share was -3.03.

In the last 12 months, operating cash flow was -12.01M and capital expenditures -1.97M, giving a free cash flow of -13.98M billion.

Bioceltix SA pays an annual dividend of ―, resulting in a dividend yield of ―

Bioceltix SA upcoming earnings date is Sep 23, 2026, TBA (Confirmed).

Bioceltix SA as a current ratio of 32.51, with Debt / Equity ratio of ―

In the past 12 months, Bioceltix SA has paid -15.38K in taxes.

Bioceltix SA EV to EBITDA ratio is -19.22, with an EV/FCF ratio of -22.73.

Bioceltix SA has zł68.40M in cash and marketable securities with zł235.30K in debt, giving a net cash position of zł68.09M billion.

Gross margin is ―, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Bioceltix SA is ―, which is 11.43% higher than the current price. The consensus rating is ―